Investor Presentation First Nine Months of 2023

13 Investor presentation First nine months of 2023 Novo NordiskⓇ Novo Nordisk has agreed to acquire the asset ocedurenone from KBP Biosciences to strengthen cardiovascular pipeline Acquisition of Ocedurenone from KBP Biosciences supports Novo Nordisk's aspiration within other serious chronic diseases therapeutic focus Innovation and Further raise the innovation-bar for diabetes treatment Develop a leading portfolio of superior treatment solutions for obesity Strengthen and progress the Rare disease pipeline Establish presence in Other serious chronic diseases focusing on CVD, MASH and CKD Ocedurenone is being developed for uncontrolled hypertension with potential further application in CVD and CKD $ до Novo Nordisk acquired Ocedurenone for up to USD 1.3 billion Ocedurenone is an oral small molecule, non-steroidal mineralocorticoid receptor antagonist Ocedurenone appeared to have an efficacious, safe and well- tolerated profile in clincial trials Asset currently examined in phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced CKD Next steps: Initiate phase 3 trials in additional cardiovascular and kidney disease indications CVD: Cardiovascular Disease; CKD: Chronic Kidney Disease; MASH: Metabolic dysfunction-associated steatohepatitis

View entire presentation